A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

Adequate hematological function defined by absolute neutrophil count,  1.5 d7 10^9/L, platelet count  100 d7 10^9/L, and hemoglobin  9 g/dL, and without growth factor treatment or blood transfusion within 2 weeks before the study intervention start. Adequate hepatic function defined by total bilirubin level  1.5 d7 upper limit of normal (ULN), aspartate aminotransferase (AST) level  3 d7 ULN, and an alanine aminotransferase (ALT) level  3 d7 ULN. Adequate renal function defined by creatinine clearance > 60 mL/min according to the Cockcroft-Gault equation or creatinine levels <1.5 mg/dl. Adequate coagulation laboratory assessments, as follows: Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN), or international normalized ratio (INR) < 1.5 or within target range if on prophylactic anticoagulation therapy.